吡格列酮对高糖刺激下大鼠肾小球系膜细胞氧化应激及纤溶酶原激活物抑制物1表达的影响

来源 :中国糖尿病杂志 | 被引量 : 0次 | 上传用户:yunguii
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的观察吡格列酮对高糖刺激下大鼠肾小球系膜细胞(MCs)氧化应激和纤溶酶原激活物抑制物1(PAI-1)表达的影响,探讨其肾脏保护机制。方法体外培养大鼠肾小球MCs,设立正常对照(NC)组、高糖(HG)组、高糖+不同浓度吡格列酮(PIO1、PIO2、PIO3)组。以荧光探针2′,7′-二氯双氢荧光素二乙酸酯(DCFH-DA)标记细胞,采用流式细胞仪检测MCs内活性氧簇(ROS)水平;以RT-PCR检测PAI-1的mRNA表达;采用ELISA检测培养细胞上清液PAI-1蛋白浓度。结果与NC组相比,高糖刺激MCs 48h后,细胞内ROS水平升高,MCs PAI-1mRNA表达和上清液PAI-1蛋白浓度增高;与HG组相比,经吡格列酮干预48h后,PIO1、PIO2、PIO3组细胞内ROS水平降低,MCs PAI-1mRNA表达和上清液PAI-1蛋白浓度降低,并呈一定的浓度依赖性。相关性分析显示,MCs内ROS水平与PAI-1mRNA表达、上清液PAI-1蛋白浓度均呈正相关。结论吡格列酮可抑制高糖诱导的大鼠肾小球MCs ROS生成和PAI-1过度表达,并呈一定的浓度依赖性,该作用可能部分与其肾脏保护有关。 Objective To observe the effect of pioglitazone on oxidative stress and plasminogen activator inhibitor 1 (PAI-1) expression in rat mesangial cells (MCs) stimulated by high glucose and explore its mechanism of renal protection. Methods Rat glomerular MCs were cultured in vitro. Normal control (NC) group, high glucose (HG) group, high glucose + pioglitazone (PIO1, PIO2, PIO3) groups were established. The cells were labeled with fluorescent probe 2 ’, 7’-dichlorodihydrofluorescein diacetate (DCFH-DA), and the level of reactive oxygen species (ROS) in MCs was detected by flow cytometry; PAI -1 mRNA expression in supernatant of culture supernatant PAI-1 protein by ELISA. Results Compared with NC group, the intracellular ROS level increased and the expression of PAI-1mRNA and PAI-1 protein in MCs increased after 48h stimulation with high glucose. Compared with HG group, after 48h intervention with Pioglitazone, PIO1 PIO2 and PIO3 decreased the level of ROS, the expression of PAI-1 mRNA in MCs and the concentration of PAI-1 in supernatant decreased in a concentration-dependent manner. Correlation analysis showed that ROS levels in MCs were positively correlated with PAI-1mRNA expression and PAI-1 protein concentration in supernatant. Conclusion Pioglitazone can inhibit the high glucose-induced glomerular MCs ROS generation and PAI-1 overexpression, and in a concentration-dependent manner, this effect may be partly related to its renal protection.
其他文献
目的探讨外周血单核细胞Toll样受体2、4(TLR2、TLR4)的表达与糖尿病慢性肾脏疾病(CKD)发生的关系。方法测定60例糖尿病患者(T2DM组)及68例早期CKD患者(CKD组)外周血单核细胞T
目的探讨不同时期糖尿病慢性肾脏疾病(CKD)患者血清可溶性CD40配体(sCD40L)水平变化。方法根据UAER将93例T2DM患者分为正常白蛋白尿(NA)组38例,微量白蛋白尿(MA)组29例和临床
目的 通过观察糖尿病慢性肾脏疾病(CKD)患者厄贝沙坦治疗后血浆氨基末端脑钠肽前体(NT-proBNP)水平变化,探讨NT-proBNP在CKD患者中的临床意义. 方法 选择T2DM患者167例,根据
患者男性,75岁。2年前确诊为膀胱移行细胞癌2级,行部分膀胱切除术,近期因阴囊湿疹不愈就诊。查体:见双侧阴囊皮肤糜烂、隆起。行阴囊皮肤组织活检术,同时行膀胱活检术发现膀
目的探讨T2DM慢性肾脏疾病(CKD)患者血清胱抑素C(Cys-C)改变及临床意义。方法选取CKD患者83例、T2DM患者98例及健康对照(NC)者100名,比较各组血清Cys-C、β2微球蛋白(β2-MG)
目的探讨T2DM血清尿酸(SUA)水平与UAlb及代谢异常的关系。方法对1363例T2DM住院患者的病历资料进行回顾性研究。结果正常白蛋白尿、微量白蛋白尿、大量白蛋白尿SUA水平分别为
目的探讨T2DM患者尿白蛋白排泄率(UAER)与外周血淋巴细胞活化的关系。方法纳入100例T2DM患者,根据UAER水平,分为不伴白蛋白尿(A)组和伴有白蛋白尿(B)组,并设健康对照(C)组,分
目的观察T2DM患者血清血管生成素2(Ang-2)水平,探讨其与糖尿病微血管病变的关系。方法将64例T2DM患者分为单纯糖尿病(T2DM)组28例及糖尿病慢性肾脏疾病(CKD)组36例,另选健康
目的观察三七对糖尿病肾病(DN)大鼠的治疗效果,探讨其作用机制,为糖尿病及DN的预防及治疗提供参考。方法予不同剂量三七治疗8周,观察其对STZ诱导的DN大鼠肾脏功能及结构的影
目的 观察不同浓度非诺贝特对高糖培养的足细胞的影响,探讨糖尿病肾病(DN)的早期机制. 方法 分离收集大鼠肾小球并进行足细胞原代培养,分为正常糖(NG)组,高糖(HG)组,非诺贝特